Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.

Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, Guigues A, Merle C, Atoui N, Fernandez C, Le Moing V, Barbuat C, Marin G, Nagot N, Sotto A, Eliaou JF, Sabatier R, Reynes J, Corbeau P.

EBioMedicine. 2016 Jun;8:265-76. doi: 10.1016/j.ebiom.2016.05.008. Epub 2016 May 10.

2.

Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis.

Sabatier R, Sabiani L, Zemmour C, Taix S, Chereau E, Gonçalves A, Jalaguier-Coudray A, Charafe-Jauffret E, Resbeut M, Extra JM, Viens P, Tallet A.

Breast. 2016 Jun;27:8-14. doi: 10.1016/j.breast.2015.12.003. Epub 2016 Mar 19.

PMID:
27212694
3.

In Vitro Corticogenesis from Embryonic Stem Cells Recapitulates the In Vivo Epigenetic Control of Imprinted Gene Expression.

Bouschet T, Dubois E, Reynès C, Kota SK, Rialle S, Maupetit-Méhouas S, Pezet M, Le Digarcher A, Nidelet S, Demolombe V, Cavelier P, Meusnier C, Maurizy C, Sabatier R, Feil R, Arnaud P, Journot L, Varrault A.

Cereb Cortex. 2016 Apr 19. pii: bhw102. [Epub ahead of print]

PMID:
27095822
4.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.82. [Epub ahead of print]

PMID:
27042835
5.

Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Apr;57:118-26. doi: 10.1016/j.ejca.2016.01.005. Epub 2016 Feb 23.

PMID:
26918737
6.

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.

Sabatier R, Lavit E, Moretta J, Lambaudie E, Noguchi T, Eisinger F, Cherau E, Provansal M, Livon D, Rabayrol L, Popovici C, Charaffe-Jauffret E, Sobol H, Viens P.

Fam Cancer. 2016 Feb 1. [Epub ahead of print]

PMID:
26833043
7.

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.

Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees.

Circ Heart Fail. 2016 Jan;9(1). pii: e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.

8.

METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.

Launay S, Sabatier R, Brunelle S, Esterni B, Tarpin C, Viret F, Gravis G, Cappiello M, Provansal M, Extra JM, Bertucci F, Viens P, Goncalves A.

Anticancer Res. 2016 Jan;36(1):293-9.

PMID:
26722056
9.

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.

Rahal S, Boher JM, Extra JM, Tarpin C, Charafe-Jauffret E, Lambaudie E, Sabatier R, Thomassin-Piana J, Tallet A, Resbeut M, Houvenaeghel G, Laborde L, Bertucci F, Viens P, Gonçalves A.

BMC Cancer. 2015 Oct 14;15:697. doi: 10.1186/s12885-015-1746-3.

10.

Extracorporeal Life Support for Refractory Cardiac Arrest or Shock: A 10-Year Study.

Brunet J, Valette X, Ivascau C, Lehoux P, Sauneuf B, Dalibert Y, Masson R, Sabatier R, Buklas D, Seguin A, Terzi N, du Cheyron D, Parienti JJ, Daubin C.

ASAIO J. 2015 Nov-Dec;61(6):676-81. doi: 10.1097/MAT.0000000000000282.

PMID:
26366684
11.

Transradial versus transfemoral approach for percutaneous coronary intervention in cardiogenic shock: A radial-first centre experience and meta-analysis of published studies.

Roule V, Lemaitre A, Sabatier R, Lognoné T, Dahdouh Z, Berger L, Milliez P, Grollier G, Montalescot G, Beygui F.

Arch Cardiovasc Dis. 2015 Nov;108(11):563-75. doi: 10.1016/j.acvd.2015.06.005. Epub 2015 Sep 11.

PMID:
26365478
12.

Antecubital vs Femoral Venous Access for Right Heart Catheterization: Benefits of a Flashback.

Roule V, Ailem S, Legallois D, Dahdouh Z, Lognoné T, Bergot E, Grollier G, Milliez P, Sabatier R, Beygui F.

Can J Cardiol. 2015 Dec;31(12):1497.e1-6. doi: 10.1016/j.cjca.2015.04.026. Epub 2015 Apr 30.

PMID:
26277087
13.

[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].

Guerin M, Sabatier R, Gonçalves A.

Bull Cancer. 2015 Apr;102(4):390-7. doi: 10.1016/j.bulcan.2015.02.007. Epub 2015 Mar 16. French.

PMID:
25790739
14.

Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.

Sabatier R, Calderon B Jr, Lambaudie E, Chereau E, Provansal M, Cappiello MA, Viens P, Rousseau F.

Int J Gynecol Cancer. 2015 Jun;25(5):815-22. doi: 10.1097/IGC.0000000000000418.

PMID:
25768081
15.

Prognostic and predictive value of PDL1 expression in breast cancer.

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F.

Oncotarget. 2015 Mar 10;6(7):5449-64.

16.

Trade-offs between pasture production and farmland bird conservation: exploration of options using a dynamic farm model.

Sabatier R, Teillard F, Rossing WA, Doyen L, Tichit M.

Animal. 2015 May;9(5):899-907. doi: 10.1017/S175173111400281X. Epub 2014 Dec 3.

PMID:
25466165
17.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators.

Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.

18.

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.

Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F.

Mol Cancer. 2014 Oct 2;13:228. doi: 10.1186/1476-4598-13-228.

19.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees.

N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.

20.

[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].

Sabatier R, Gonçalves A.

Bull Cancer. 2014 Jul-Aug;101(7-8):765-71. doi: 10.1684/bdc.2014.1940. French.

PMID:
25091659
Items per page

Supplemental Content

Loading ...
Write to the Help Desk